Cybin Corp., a Canada-based, life-science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, recently announced the appointment of Doug Drysdale as the company’s chief executive officer. Well recognized in the pharmaceutical space, Drysdale brings more than three decades of experience and a recognition of psychedelics as a major breakthrough in treating mental health conditions. Amid the recent strong push for research and commercialization in the psychedelics sector, Drysdale seeks to pursue emerging opportunities and pave the road for the company’s rapid growth. “I am beyond excited to be joining the Cybin team,” Drysdale stated in a recent article of his new role. “I believe Cybin’s business model and talented management team uniquely position the company to examine the efficacy of psychedelic-based therapies and delivery systems in treating mental illness and addiction disorders. I expect the company’s expanding development pipeline will allow Cybin to additionally explore a cost-effective and timely array of health-care alternatives. We will continue to organically grow our IP portfolio and shall be looking to add to our IP through accretive acquisitions.”
To view the full article, visit https://ibn.fm/njuAt
About Cybin Corp.
Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.